Cellyan Biotechnology (HKPD) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$13.4M

Revenue (quarter)

$13.4M

Revenue growth (year over year)

−33.87%

Gross profit (trailing twelve months)

$1.4M

Gross margin

10.32%

Net income (trailing twelve months)

−$1.1M

Net income (quarter)

−$1.1M

Net income growth (year over year)

−4098.56%

Net margin

−8.46%

Return on equity

−15.59%

EPS (trailing twelve months)

−$0.07

Book value per share

$0.41

P/E (trailing twelve months)

—

Price to book

0.53

Debt to assets

25.39%

Payout ratio

—

Dividend yield

—

Company profile

Cellyan Biotechnology Co Ltd is an integrated pharmaceutical cross-border e-commerce supply chain service provider with a professional team and related pharmaceutical storage facilities in Hong Kong. It operates through two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, referred to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, referred to as the Procurement and Distribution division. Its main business provides one-stop services for merchants engaged in cross-border pharmaceutical e-commerce, including OTC wholesale, import and export, warehousing, packaging, customs clearance and delivery to final destinations, forming a closed loop of pharmaceutical cross-border e-commerce supply chain.

• Is Cellyan Biotechnology (HKPD) profitable?

  No. Cellyan Biotechnology reported a net loss of $1.1M over the trailing twelve months.

• How much revenue does Cellyan Biotechnology (HKPD) make?

  Cellyan Biotechnology generated $13.4M in revenue over the trailing twelve months, down 33.87% year over year.

• How do I buy stock in Cellyan Biotechnology (HKPD)?

  HKPD trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.